Eileen Marshall

Cooley advised Heliogen, a provider of on-demand clean energy technology solutions, on its definitive agreement with Zeo Energy, a Florida-based provider of residential solar and energy efficiency solutions, representing the culmination of Heliogen’s review of strategic alternatives and pursuant to which Zeo will acquire all of Heliogen’s outstanding equity securities in an all-stock transaction.

Cooley advised Kudu Dynamics, a company developing state-of-the-art cyber capabilities and nonkinetic effects against a variety of military-relevant systems, on its sale to Leidos (NYSE: LDOS), an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations.

Cooley advised BioMarin Pharmaceutical (Nasdaq: BMRN), a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient, on its definitive agreement to acquire Inozyme Pharma for $4 per share in an all-cash transaction valued at approximately $270 million.

Cooley advised Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, on its strategic partnership to develop and commercialize siRNA therapies with CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases.

Cooley advised Uber Technologies (NYSE: UBER), a technology platform that uses a massive network, top technology, operational excellence and deep product knowledge to power movement from Point A to Point B, on its offering of $1 billion principal amount of 0% exchangeable senior notes due 2028.